O'Rourke P Pearl, Carrithers Judith, Patrick-Lake Bray, Rice Todd W, Corsmo Jeremy, Hart Raffaella, Drezner Marc K, Lantos John D
Human Research Affairs, Partners HealthCare, Boston, MA, USA
School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Clin Trials. 2015 Oct;12(5):449-56. doi: 10.1177/1740774515597685. Epub 2015 Sep 15.
The oversight of research involving human participants is a complex process that requires institutional review board review as well as multiple non-institutional review board institutional reviews. This multifaceted process is particularly challenging for multisite research when each site independently completes all required local reviews. The lack of inter-institutional standardization can result in different review outcomes for the same protocol, which can delay study operations from start-up to study completion. Hence, there have been strong calls to harmonize and thus streamline the research oversight process. Although the institutional review board is only one of the required reviews, it is often identified as the target for harmonization and streamlining. Data regarding variability in decision-making and interpretation of the regulations across institutional review boards have led to a perception that variability among institutional review boards is a primary contributor to the problems with review of multisite research. In response, many researchers and policymakers have proposed the use of a single institutional review board of record, also called a central institutional review board, as an important remedy. While this proposal has merit, the use of a central institutional review board for multisite research does not address the larger problem of completing non-institutional review board institutional review in addition to institutional review board review—and coordinating the interdependence of these reviews. In this article, we describe the overall research oversight process, distinguish between institutional review board and institutional responsibilities, and identify challenges and opportunities for harmonization and streamlining. We focus on procedural and organizational issues and presume that the protection of human subjects remains the paramount concern. Suggested modifications of institutional review board processes that focus on time, efficiency, and consistency of review must also address what effect such changes have on the quality of review. We acknowledge that assessment of quality is difficult in that quality metrics for institutional review board review remain elusive. At best, we may be able to assess the time it takes to review protocols and the consistency across institutions.
对涉及人类受试者的研究进行监督是一个复杂的过程,需要机构审查委员会的审查以及多个非机构审查委员会的机构审查。当每个研究地点独立完成所有所需的当地审查时,这个多方面的过程对于多地点研究来说尤其具有挑战性。机构间缺乏标准化可能导致同一方案产生不同的审查结果,这可能会延误从研究启动到完成的整个研究操作过程。因此,人们强烈呼吁协调并简化研究监督过程。虽然机构审查委员会只是所需审查之一,但它常常被视为协调和简化的目标。关于各机构审查委员会在决策和法规解释方面存在差异的数据,导致人们认为机构审查委员会之间的差异是多地点研究审查问题的主要原因。对此,许多研究人员和政策制定者提议使用单一的记录机构审查委员会,也称为中央机构审查委员会,作为一项重要的补救措施。虽然这一提议有其优点,但在多地点研究中使用中央机构审查委员会并不能解决除机构审查委员会审查之外完成非机构审查委员会机构审查以及协调这些审查之间相互依存关系这个更大的问题。在本文中,我们描述了整体的研究监督过程,区分了机构审查委员会和机构的职责,并确定了协调和简化过程中的挑战与机遇。我们关注程序和组织问题,并假定保护人类受试者仍然是首要关注点。针对机构审查委员会程序提出的侧重于审查时间、效率和一致性的修改建议,也必须考虑这些变化对审查质量有何影响。我们承认评估质量很困难,因为机构审查委员会审查的质量指标仍然难以捉摸。充其量,我们也许能够评估审查方案所需的时间以及各机构之间的一致性。